Mesa Laboratories (NASDAQ:MLAB) Given New $94.00 Price Target at Wells Fargo & Company

Mesa Laboratories (NASDAQ:MLAB) had its price objective raised by research analysts at Wells Fargo & Company from $83.00 to $94.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s target price points to a potential downside of 3.04% from the stock’s previous close.

A number of other brokerages also recently weighed in on MLAB. Wall Street Zen upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Mesa Laboratories in a research report on Thursday, January 22nd. Finally, Zacks Research raised Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $94.00.

Mesa Laboratories Trading Up 10.8%

Shares of NASDAQ:MLAB traded up $9.42 during midday trading on Wednesday, hitting $96.95. 30,114 shares of the stock were exchanged, compared to its average volume of 95,186. The stock has a market capitalization of $535.16 million, a price-to-earnings ratio of -302.67 and a beta of 0.89. The business’s 50-day moving average price is $81.41 and its 200 day moving average price is $74.49. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.44 and a current ratio of 2.02. Mesa Laboratories has a 12 month low of $55.45 and a 12 month high of $155.12.

Institutional Investors Weigh In On Mesa Laboratories

Several institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC raised its position in Mesa Laboratories by 17,733.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 535 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 532 shares during the period. CWM LLC boosted its holdings in shares of Mesa Laboratories by 48.9% in the third quarter. CWM LLC now owns 597 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 196 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Mesa Laboratories by 30.9% during the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 243 shares during the period. Tower Research Capital LLC TRC grew its holdings in Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after acquiring an additional 684 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Mesa Laboratories during the third quarter valued at approximately $178,000. Institutional investors own 90.60% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.